Chief AI Office
Posts
📌 8 AI Startups raise $400M+

📌 8 AI Startups raise $400M+

BONUS: The State of Generative AI in the Enterprise From Menlo Ventures

November 21, 2024

TODAY’S FUNDING RECAP 🗓️

New Lantern raises a $19M Series A — Radiology copilot
Twine raises a $12M Seed — AI employees for cybersecurity teams
Converge Bio raises a $5.5M Seed — Biotech LLMs
5 more rounds caught by my funding tracker

Read time: 2 minutes

1500+ AI STARTUPS TO BOOST Q4 REVENUE

Download our Funding Database for $99 (50% off)

The most comprehensive database of 1500+ funding rounds in AI this year.

The database comes with:

Round information
Investor information
Enhanced company descriptions written with GPT-4o

Download it now — Use the code “Q4” to get the discount at checkout [42 downloads remaining]

TOP PICKS 📢

1/3

→ New Lantern

Amount: $19M 🎉

Round: Series A

Lead Investor: Benchmark

New Lantern is an AI radiology platform that combines two primary tools used by radiologists: PACS (to view scans) and reporting software.

The platform incorporates AI to automate tedious and time-consuming tasks like taking 3D measurements of scans, writing reports, organ classification, etc.

2/3

→ Twine

Amount: $12M 🎉

Round: Seed

Lead Investor: Dell Technologies Capital, Ten Eleven Ventures

Twine offers AI employees for cybersecurity teams.

These digital employees are AI agents capable of executing specific cybersecurity tasks from start to finish. Twine's first digital employee, named "Alex," orchestrates the entire Identity Access Management (IAM) process, including planning, approval, and execution of identity workflows.

Why Ten Eleven Ventures invested

3/3

→ Converge Bio

Amount: $5.5M 🎉

Round: Seed

Lead Investor: TLV Partners

Converge Bio integrates biology-focused large language models (LLMs) into the R&D processes of pharmaceutical and biotech companies.

The platform enhances foundational models by performing three key tasks:

Enriches raw LLMs with domain-specific knowledge, such as antigen-antibody and protein-protein interactions.
Fine-tuned on proprietary data from the company’s research efforts.
Provide explainable outputs so researchers can pinpoint why certain sequences work better than others